$0.8047
-0.0316[-3.78%]
At close: Apr 25
$0.8047
0[0.00%]
After Hours: 4:08PM EDT
Viracta Therapeutics
(NASDAQ:VIRX)Viracta Therapeutics Stock (NASDAQ:VIRX), Analyst Ratings, Price Targets, Predictions
Viracta Therapeutics Inc has a consensus price target of $7.6, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co. on April 17, 2024, April 16, 2024, and March 12, 2024. With an average price target of $7 between Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 769.89% upside for Viracta Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
RBC Capital
SVB Securities
EF Hutton
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Viracta Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 1515.51% | Oppenheimer | Hartaj Singh | → $13 | Maintains | Outperform | Get Alert |
| 04/16/2024 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 397.08% | HC Wainwright & Co. | Robert Burns | → $4 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 397.08% | HC Wainwright & Co. | Robert Burns | → $4 | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 397.08% | HC Wainwright & Co. | Robert Burns | $10 → $4 | Maintains | Buy | Get Alert |
| 11/10/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 645.62% | RBC Capital | Gregory Renza | $7 → $6 | Maintains | Outperform | Get Alert |
| 10/05/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 769.89% | RBC Capital | Gregory Renza | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 769.89% | RBC Capital | Gregory Renza | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 521.35% | SVB Securities | Andrew Berens | $10 → $5 | Maintains | Outperform | Get Alert |
| 08/15/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 1142.7% | HC Wainwright & Co. | Robert Burns | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 1142.7% | EF Hutton | Tony Butler | → $10 | Initiates | → Buy | Get Alert |
| 07/05/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 1142.7% | HC Wainwright & Co. | Robert Burns | $33 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 4000.91% | HC Wainwright & Co. | Robert Burns | $35 → $33 | Maintains | Buy | Get Alert |
| 05/09/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 769.89% | RBC Capital | Gregory Renza | $8 → $7 | Maintains | Outperform | Get Alert |
| 05/08/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 1266.97% | SVB Securities | Andrew Berens | $11 → $11 | Maintains | Outperform | Get Alert |
| 03/27/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 1888.32% | Oppenheimer | Hartaj Singh | $14 → $16 | Maintains | Outperform | Get Alert |
| 03/14/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 894.16% | RBC Capital | Gregory Renza | → $8 | Reiterates | → Outperform | Get Alert |
| 03/14/2023 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 4249.45% | HC Wainwright & Co. | Robert Burns | → $35 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 894.16% | RBC Capital | Gregory Renza | $10 → $8 | Maintains | Outperform | Get Alert |
| 11/10/2022 | VIRX | Buy Now | Viracta Therapeutics | $0.80 | 1266.97% | SVB Securities | Andrew Berens | → $11 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Viracta Therapeutics (VIRX)?
The latest price target for Viracta Therapeutics (NASDAQ: VIRX) was reported by Oppenheimer on April 17, 2024. The analyst firm set a price target for $13.00 expecting VIRX to rise to within 12 months (a possible 1515.51% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viracta Therapeutics (VIRX)?
The latest analyst rating for Viracta Therapeutics (NASDAQ: VIRX) was provided by Oppenheimer, and Viracta Therapeutics maintained their outperform rating.
When was the last upgrade for Viracta Therapeutics (VIRX)?
There is no last upgrade for Viracta Therapeutics.
When was the last downgrade for Viracta Therapeutics (VIRX)?
There is no last downgrade for Viracta Therapeutics.
When is the next analyst rating going to be posted or updated for Viracta Therapeutics (VIRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Viracta Therapeutics (VIRX) correct?
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $0.00 to $13.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.